This study aims to provide safety information on the ligand, GSK2315698A. The
pharmacokinetics and pharmacodynamics of the ligand will be determined together with the
differences in routes of dose administration, namely the tolerability between intravenous
versus subcutaneous dose administration. The study will be carried out in patients with
systemic amyloidosis and the ability of GSK2315698A in depleting levels of serum amyloid
protein (SAP) will be measured.